Archives des sur-page-accueil

Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases

Apr 27, 2026

Labège, France, April 27, 2026 — Antabio, a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections identified by WHO and CDC as critical priorities, today highlighted the presentation of new data on...

Antabio and GARDP join forces to identify potential next-generation antibiotics

Mar 23, 2026

Geneva/Labège, 23 March 2026. The French biotech company Antabio and the GARDP Foundation (known as GARDP) today announced a joint effort to accelerate crucial early-stage antibiotic discovery, responding to a steep rise in drug-resistant infections...

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections

Sep 3, 2024

Labège, France, September 3rd, 2024. Antabio, a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens, with a particular focus on life-threatening respiratory infections, today announced...